Calcitonin preparations have recently been introduced in clinical therapeutics for various metabolic bone diseases, especially osteoporosis. While the analgesic effect of calcitonins on lumbago and backache in osteoporosis has been well recognized, scarecely any detailed reports are yet available as to the effect of calcitonins on osteopenia, the main bone manifestation of osteoporosis.
In the present study, 10 units, [Asu
1, 7]-Eel calcitonin (Elcatonin), a synthetic derivative of eel calcitonin, was injected intramuscularly at 2-4 day intervals over a period of 3-12 months. Patients with osteoporosis were divided into two groups according to the serum calcium value at the beginning of treatment, those with serum calcium 9.0mg/d
l, to evaluate the effect of Elcatonin on blood biochemical data and bone mass. Bone mass kept decreasing in osteoporosis with serum calcium <9.0mg/d
l despite Elcatonin treatment, whereas bone mass kept unchanged in the group with serum calcium ≥9.0mg/d
l, suggesting the importance of initial serum calcium level in predicting the effect of Elcatonin on bone mass.
抄録全体を表示